Compare SSBI & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSBI | PMVP |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | 106 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.7M | 79.5M |
| IPO Year | N/A | 2020 |
| Metric | SSBI | PMVP |
|---|---|---|
| Price | $13.30 | $1.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.9K | ★ 894.8K |
| Earning Date | 04-28-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.60 | $0.82 |
| 52 Week High | $14.00 | $1.88 |
| Indicator | SSBI | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 41.81 |
| Support Level | $12.73 | $1.26 |
| Resistance Level | $13.58 | $1.50 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 100.00 | 2.56 |
Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.